



# Managing the Highs and Lows of Mitochondrial Disease: a review and updates on diabetes and hypoglycemia


Herodes Guzman, MD, MPH &  
Shana McCormack, MD, MTR



October 4, 2024

# Mitochondrial disease affects endocrine function

- **Mitochondrial diabetes** is the most common endocrine disorder
- **Hypoglycemia** or low blood sugar is also seen in mitochondrial disease, affecting diabetes management




Reference PMID: 34644386



# Endocrine-related hospitalizations

- In one study, 7% of hospital admissions were due to endocrine disease (all blood sugar related)



# Mitochondrial Diabetes


# The most common mitochondrial endocrine disorder

- Mitochondrial diabetes affects 2% of children with mitochondrial disease
- Affects 24% of adults with mitochondrial disease


Mitochondrial disease (genotype)	Prevalence estimates (all ages)
<b>OVERALL</b>	<b>15%</b>
m.3243A>G (MELAS, MIDD)	~40%
m.14709T>C	50%
SLSMDS	10-15%
m.8344A>G (MERRF)	~10%
m.11778G>A	7%
Multiple mtDNA mutations	7%
RRM2B (AR, AD)	3-5%
OPA1 (AR, AD)	4%
POLG (AR, AD)	3-11%
Others	-

Among genotype; from small studies; AR: autosomal recessive; AD: autosomal dominant

# What is a normal blood sugar?



# Mitochondrial diabetes symptoms\*



- **Emergencies:**
  - Diabetic ketoacidosis
  - Hyperosmolar hyperglycemia

# Mitochondrial diabetes is different

- **Type 1 Diabetes**

- Autoimmune injury leads to insulin deficiency

- **Type 2 Diabetes**

- Increased insulin resistance leads to beta cell failure and eventual insulin deficiency

- **Mitochondrial diabetes**

- Thought to be due to a combination of both insulin deficiency and insulin resistance



**There are no evidence-supported practices  
specific to mitochondrial diabetes**

# Our Approach: for those at risk

- Yearly surveillance
  - Hemoglobin A1c
  - Fructosamine
  - Blood sugar checks (for 3 days prior to visit)
    - First thing in the morning
    - 2 hours after the largest meal of the day

If there is ketosis/dehydration/weight loss...


- Start insulin therapy

If there is none of the above...


- Consider oral therapies

# Our Approach: management considerations

- Insulin therapy
  - Multiple daily injections (basal/bolus vs. 70/30)



Insulin Pen Parts



- Insulin pumps

# Our Approach: management considerations

- Oral medications
  - Sulfonylureas (hypoglycemia risk)
  - GLP-1 receptor agonists (can present a problem for gut dysmotility and pancreatitis)
  - Tirzepatide (dual GIP and GLP-1 receptor agonist)
  - Consider metformin (lactic acidosis risk)
  - Consider SGLT2 inhibitors (ketoacidosis risk)
  - Consider DPP4 inhibitors (in adults)
- Under study:
  - Imeglimin





# Our Approach: management considerations

- Blood sugar monitoring
  - Finger stick blood sugars



- Continuous glucose monitors


# Our Approach: management considerations

- Hypoglycemia rescue
  - Premixed, intranasal, injectable glucagon



# Summary

- *Insulin secretion* requires mitochondrial ATP production
- *Insulin resistance* (e.g., in muscle) can occur
- **Educate** regarding symptoms
- **Screen** annually
- **Manage** based on physiology, including blood ketones
- Select medications based on **comorbidities** and risk for off-target effects
- Use **technology** (CGM, pumps) where possible



\*Wolfram syndrome, Friedreich ataxia, myotonic dystrophy type I

# Hypoglycemia



# Hypoglycemia in mitochondrial disease

- Overall estimated prevalence of ~19% among patients with mitochondrial disease without diabetes





Fig. 1. Glucose values for every study subject (n = 116).


# Hypoglycemia symptoms\*

- Can progress to seizures and unresponsiveness




# Hypoglycemia types

- When evaluating, we divide into **ketotic** and **non-ketotic hypoglycemia**
- Often, “**fasting**” hypoglycemia is **ketotic**
- Often, “**reactive**” hypoglycemia is **non-ketotic**
- Some individuals with metabolic disorders **cannot produce ketones**



# Hypoglycemia evaluation

- Inpatient diagnostic fasting studies (controlled monitoring)
- Compare mitochondrial disease (suspected, confirmed) to idiopathic ketotic hypoglycemia
- **Fasting time was shorter, and ketone production was less**




Patrick Hanley, CHOP/Nemours



# Causes of hypoglycemia in mitochondrial disease

- Inherent to mitochondrial disease
- Liver dysfunction
- Malnutrition
- Reactive hypoglycemia
- Adrenal insufficiency
- Growth hormone deficiency
- Diabetes management (i.e., from insulin overdose or oral hypoglycemics)



# Hypoglycemia management

## Emergency

- Push dextrose fluids (D10)
- Avoid hyperglycemia (lactate risk)
- May need dextrose + insulin drip


*Have an  
emergency  
plan and  
letter*

## • Maintenance

- Use D5 maintenance fluids until tolerating regular diet
- Avoid prolonged fasting
- Restart complete nutrition as soon as possible


# Hypoglycemia management

- **Check blood sugar** when
  - symptomatic
  - after longest usual fasting period
- Goal blood sugar at least 70 mg/dL
  - <50 mg/dL is an **emergency**
- **Check blood ketones (BHB)**
- Next steps are based on findings
  - Surveillance
  - Rescue
  - Support
- **Watch out for NPO status!**



# Adrenal insufficiency

- Mitochondria are critical for **steroid synthesis**
- Symptoms of adrenal insufficiency (especially with critical illness)
  - Low blood sugar
  - Low blood pressure
  - Low sodium levels
  - High potassium levels



Williams, 12<sup>th</sup> edition



# Adrenal insufficiency: who needs testing?

- History of having received steroid medications (e.g., prednisone)
- Individuals with suggestive symptoms warrant testing
- Empiric “stress dose steroids” are sometimes given in ICU settings

**Table 1.** Descriptive statistics of clinical characteristics in pediatric intensive care unit (PICU) patients with and without mitochondrial disease.


Factor	Mitochondrial disease	Other diagnoses
Age in years, median (IQR)	7.6 (9.0)	4.6 (11.6)
Length of stay in days, median (IQR)	2.9 (5.6)	1.7 (2.9)
Mortality, % deceased	5.2%	2.4%
PRISM score median (IQR)	3 (6)	2 (5)
PIM2 score (IQR)	−3.38 (1.88)	−4.74 (2.02)
Hours on ventilator, median (IQR)	71.5 (187.7)	14.0 (49.5)

*IQR* interquartile range.


PMID: 33627817

# Adrenal insufficiency

- **Screening**
  - 8a ACTH
  - cortisol
  - *PRA/aldosterone, DHEAS*
- **Provocative testing**
- **Steroid replacement**
  - Glucocorticoid/mineralocorticoid
  - Formulation
  - Daily
  - Stress-dose
- **Adverse effects (iatrogenic Cushing's)**



# Growth hormone deficiency



- **Management**

- Growth hormone injections (daily vs weekly)

- **Risks**

- Diabetes development

# Summary

- Endocrine disorders are prevalent in individuals with mitochondrial disease
- Evidence-supported and symptom-directed patient screening is appropriate
- Identify opportunities for effective interventions




Figure 2 | **Endocrine dysfunction in mitochondrial disease and their associated gene defects.** Endocrine dysfunction associated with primary mitochondrial disease. Genes with mutations reported in patients with dysfunction of the illustrated endocrine gland are included. mtDNA, mitochondrial DNA.

# Resources

Research Careers International Donate Now MyCH

More  Get Care Patients & Families Healthcare Professionals Locations Specialties

[← Search Conditions](#)

## Mitochondrial Disease

[Learn more about the Mitochondrial Medicine](#)

What is mitochondrial disorder?

What is Mitochondrial Disease?

HOME NEWS & UPDATES EDUCATION M3 JOURNAL MEMBERSHIP COURSES  
CARE NETWORK ABOUT DONATE CONTACT



### MITOCHONDRIAL MEDICINE SOCIETY

ADVANCING EDUCATION, RESEARCH, AND GLOBAL COLLABORATION IN CLINICAL MITOCHONDRIAL MEDICINE



### UNITED MITOCHONDRIAL DISEASE FOUNDATION

MITOCHONDRIAL DISEASE **RESOURCES** GET INVOLVED RESEARCH ABOUT US DONATE GET SUPPORT

## Resources, Answers & Support



**Thank you!**

